Hereditary Cancer Panel
Myriad myRisk® Hereditary Cancer is a scientific advancement revolutionizing hereditary cancer testing. Blending both genetic test status AND personal cancer family history, Myriad myRisk hereditary cancer panel represents the next generation of hereditary cancer risk testing. Myriad myRisk identifies elevated risk for 8 important cancers by analyzing multiple, clinically significant genes. Additionally, Myriad myRisk provides a summary of available medical society guidelines to help you optimize your patients’ medical management. Be confident you know your patients’ cancer risks and appropriate follow-up management with Myriad myRisk Hereditary Cancer.
(FDA-approved germline BRCA1/2 test) is the only companion diagnostic test intended to be used as an aid in treatment decision making for the PARP inhibitor Lynparza™ (olaparib)
Prolaris was developed to better measure disease aggressiveness by measuring the expression level of genes involved with cell proliferation. Prolaris adds critical information about prostate cancer, and, in conjunction with clinical parameters such as Gleason score and PSA, helps the physician and patient make personalized treatment decisions for prostate cancer.
Myriad myPath® Melanoma
Myriad myPath Melanoma is a unique, clinically validated, molecular test using qRT-PCR methodology to provide valuable, additive diagnostic information unavailable from any other test. At Myriad, we’ve seen the power of genetic insight to expose cancer risk and change lives. We set out to answer the need for a great certainty in diagnosing melanoma by developing a 23-gene expression signature that objectively differentiates malignant melanoma from benign nevi with a high degree of accuracy. When used in conjunction with the clinical and pathologic work-up, the result is a diagnostic test that increases confidence rather than relying on subjective analysis or poorly validated protocols in these difficult cases.
Myriad myPlan® Lung Cancer
Myriad myPlan® Lung Cancer is an RNA expression signature based on 31 cell cycle progression (CCP) genes – the genes that regulate cell division. Early-stage lung adenocarcinoma tumors with a higher myPlan® Lung Cancer Prognostic Score are predicted to be more aggressive and are associated with a higher lung cancer mortality rate than tumors with a lower score. Knowing the aggressiveness of your patients’ cancer is critical when weighing the factors involved in making treatment decisions.
Hereditary Colon Cancer
COLARIS® and COLARIS AP® assess the risk of developing hereditary colorectal cancer by detecting disease-causing mutations in the MLH1, MSH2, MSH6, PMS2, EPCAM, MYH and APC genes, which are responsible for the majority of Lynch syndrome, MYH-associated polyposis (MAP) and adenomatous polyposis syndrome cases. These results help providers and patients make more informed healthcare decisions such as earlier screenings.
Hereditary Breast & Ovarian Cancer
BRACAnalysis® testing assesses a woman’s risk of developing hereditary breast or ovarian cancer based on the detection of mutations in the BRCA1 or BRCA2 genes. Approximately 7% of breast cancer and 11 – 15% of ovarian cancer cases are caused by BRCA1 or BRCA2, which are inherited in an autosomal dominant pattern. When assessing hereditary cancer risk, a patient’s personal and family history is collected to investigate the risk for HBOC. Once a patient is identified as being at increased risk of HBOC, genetic test results provide the most accurate means of cancer risk assessment for a patient.